Xu Zhao
Impact in
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
- MicroRNA in disease regulation
- Cancer, Lipids, and Metabolism
-
- RNA modifications and cancer
- Circular RNAs in diseases
Papers in
-
- RNA modifications and cancer 8
- Circular RNAs in diseases 6
- Cancer-related gene regulation 5
-
- Cancer-related molecular mechanisms research 15
- MicroRNA in disease regulation 7
- Co-authors
- Wei Liu (1 shared paper)Guo Qiang Chen (1 shared paper)Xiaozhi Zhang (16 shared papers)Xiangjian Luo (4 shared papers)Ya Cao (4 shared papers)Yuchen Sun (12 shared papers)Can Cheng (3 shared papers)Xiaobo Shi (10 shared papers)
- Journals
- Scientific Reports (4 papers)Frontiers in Immunology (2 papers)Molecules (2 papers)Journal of Ethnopharmacology (2 papers)Pharmaceuticals (2 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Xu Zhao
60 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 119
- Cancer Research 388
- Molecular Biology 602
- Immunology 103
- Oncology 133
- Biochemistry 35
Countries citing papers authored by Xu Zhao
This map shows the geographic impact of Xu Zhao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xu Zhao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xu Zhao more than expected).
Fields of papers citing papers by Xu Zhao
This network shows the impact of papers produced by Xu Zhao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xu Zhao. The network helps show where Xu Zhao may publish in the future.
Co-authors
The 25 scholars most cited alongside Xu Zhao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 65 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Targeted genes and interacting proteins of hypoxia inducible factor-1. | 2012 | 148 |
| 2 | 2018 | 85 | |
| 3 | 2017 | 76 | |
| 4 | 2021 | 61 | |
| 5 | 2020 | 57 | |
| 6 | 2018 | 42 | |
| 7 | 2011 | 42 | |
| 8 | 2018 | 35 | |
| 9 | 2019 | 32 | |
| 10 | RIP3 mediates TCN-induced necroptosis through activating mitochondrial metabolism and ROS production in chemotherapy-resistant cancers. | 2021 | 29 |
| 11 | 2023 | 23 | |
| 12 | 2020 | 21 | |
| 13 | 2021 | 20 | |
| 14 | 2021 | 20 | |
| 15 | 2021 | 18 | |
| 16 | 2021 | 17 | |
| 17 | 2021 | 16 | |
| 18 | 2012 | 15 | |
| 19 | 2019 | 15 | |
| 20 | 2021 | 15 |
About Xu Zhao
Xu Zhao is a scholar working on Molecular Biology, Cancer Research, Epidemiology, Oncology and Surgery, having authored 65 papers that have together received 1.1k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (15 papers), RNA modifications and cancer (8 papers), MicroRNA in disease regulation (7 papers), Circular RNAs in diseases (6 papers), Cardiac, Anesthesia and Surgical Outcomes (6 papers), Cancer-related gene regulation (5 papers), Cancer Mechanisms and Therapy (4 papers) and Autophagy in Disease and Therapy (4 papers). The work is most often cited by research in Cancer Research (388 citations), Molecular Biology (602 citations), Immunology (103 citations), Oncology (133 citations) and Biochemistry (35 citations). Xu Zhao has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Wei Liu, Guo Qiang Chen, Xiaozhi Zhang, Xiangjian Luo, Ya Cao, Yuchen Sun, Can Cheng, Xiaobo Shi, Yuan Ma and Namei Li. Their work appears in journals such as Scientific Reports, Frontiers in Immunology, Molecules, Journal of Ethnopharmacology and Pharmaceuticals.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.